Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1994
|
| gptkbp:ATCCode |
N06AX06
|
| gptkbp:blackBoxWarning |
liver failure
|
| gptkbp:CASNumber |
82752-99-6
|
| gptkbp:chemicalFormula |
C25H32Cl2N6O3
|
| gptkbp:contraindication |
gptkb:liver_disease
hypersensitivity to nefazodone |
| gptkbp:drugClass |
antidepressant
serotonin antagonist and reuptake inhibitor |
| gptkbp:eliminationHalfLife |
2-4 hours
|
| gptkbp:genericName |
gptkb:nefazodone
|
| https://www.w3.org/2000/01/rdf-schema#label |
Serzone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketWithdrawalYear |
2004
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness drowsiness liver toxicity dry mouth |
| gptkbp:usedFor |
gptkb:major_depressive_disorder
|
| gptkbp:withdrawn |
gptkb:Canada
gptkb:Europe |
| gptkbp:withdrawnReason |
risk of liver failure
|
| gptkbp:bfsParent |
gptkb:Nefazodone
gptkb:nefazodone |
| gptkbp:bfsLayer |
7
|